AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05609812
Drug: Atacicept
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous (SC) injections by prefilled syringe
Trial: NCT05555199
Drug: ICG
RxNorm normalized name: ICG136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
Trial: NCT05211947
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809
Trial: NCT06182774
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose determined at enrollment
Trial: NCT06182774
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose determined at enrollment
Trial: NCT06182774
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose determined at enrollment
Trial: NCT05551936
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m\^2 IV Days 1-2, Cycles 1-3
Trial: NCT05551936
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 IV Day 1 Cycles 1-6
Trial: NCT05551936
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
Trial: NCT05634499
Drug: Giredestrant
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
Trial: NCT06402955
Drug: ketamine hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will have a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, we will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.
Trial: NCT01244607
Drug: NI-0801
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single i.v. administration
Trial: NCT04856475
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)
Trial: NCT05992220
Drug: Atezolizumab plus bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab plus bevacizumab q3w
Trial: NCT05435547
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will take Dexamethasone pre-operatively
Trial: NCT05948267
Drug: ketamine- dexmeditomidine admixure
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
Trial: NCT05948267
Drug: Propofol, Lidocaine and fentanyl
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
Trial: NCT03569553
Drug: AIGIV
RxNorm normalized name: IGIV
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthrax Immune Globulin Intravenous (Human)
Trial: NCT05559931
Drug: N,N-Dimethyltryptamine
RxNorm normalized name: N,N-dimethyltryptamine
DrugBank: Dimethyltryptamine (DB01488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over 6 hours
Trial: NCT04467723
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
Trial: NCT06218602
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT00002178
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002178
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002178
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002178
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05855083
Drug: Biological: narsoplimab
DrugBank: Narsoplimab (DB16418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with narsoplimab 4 mg/kg will be administered
Trial: NCT06418087
Drug: Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
RxNorm normalized name: Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit.
Trial: NCT06120504
Drug: SGN-35T
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given into the vein (IV; intravenously)
Trial: NCT06530082
Drug: camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
Trial: NCT05580510
Drug: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator.
Trial: NCT05580510
Drug: Empagliflozin 10 MG OD
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug.
Trial: NCT00002398
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06305754
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m\^2 via IV infusion
Trial: NCT06305754
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 mg/mL\*min via IV infusion
Trial: NCT06305754
Drug: H1 Receptor Antagonist
RxNorm normalized name: Histamine H1 receptor antagonist
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as rescue medication per approved product label
Trial: NCT06305754
Drug: H2 Receptor Antagonist
RxNorm normalized name: Histamine H2 receptor antagonist
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as rescue medication per approved product label
Trial: NCT06305754
Drug: Dexamethasone (or equivalent)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as rescue medication per approved product label
Trial: NCT06305754
Drug: Steroid Mouthwash (dexamethasone or equivalent)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as rescue medication per approved product label
Trial: NCT04617535
Drug: REGN10933+REGN10987 combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) single dose
Trial: NCT06158386
Drug: Chidamide combined with Linperlisib
RxNorm normalized name: miconazole
DrugBank: Linperlisib (DB17235)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
Trial: NCT05144698
Drug: Chemotherapy Prior to RAPA-201 Therapy
RxNorm normalized name: BRASSICA RAPA POLLEN
DrugBank: RAPA-201 (DB18446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Trial: NCT04534803
Drug: BCG Vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .1 mL of reconstituted BCG vaccine given intradermally at baseline.
Trial: NCT06467500
Drug: Cadonilimab (AK104)
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
Trial: NCT05082116
Drug: turoctocog alfa pegol (N8-GP)
RxNorm normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
Trial: NCT04858451
Drug: RESP301
RxNorm normalized name: RESP301
DrugBank: RESP301 (DB16497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day.
Trial: NCT01216124
Drug: docetaxel oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6
Trial: NCT05341817
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
Trial: NCT05341817
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
Trial: NCT05275725
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
Trial: NCT04979806
Drug: Cefepime-zidebactam (FEP-ZID)
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 g (2 g FEP + 1 g ZID) IV q8h
Trial: NCT04979806
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g IV q8h
Trial: NCT05938478
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
Trial: NCT06543381
Drug: Olutasidenib
RxNorm normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05440786
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally
Trial: NCT05440786
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05440786
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally
Trial: NCT04923945
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest. Or patient will receive Savolitinib \[Savolitinib 300 mg, po, twice per day (BID) continuously in patients with baseline weight ≥50 kg, and Savolitinib 200 mg, po, BID in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
Trial: NCT06068530
Drug: DHA/piperaquine and a SLD-PQ
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
Trial: NCT00407433
Drug: Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04672564
Drug: Carrimycin
RxNorm normalized name: Carrimycin
DrugBank: Carrimycin (DB16476)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
Trial: NCT06565728
Drug: Vitamin D3 2000 UNT Oral Tablet
RxNorm normalized name: cholecalciferol
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
Trial: NCT05103397
Drug: methyl prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
Trial: NCT05103397
Drug: Methyl Prednisolonate
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
Trial: NCT05736224
Drug: Sunscreen
RxNorm normalized name: sunscreen
DrugBank: Oxybenzone (DB01428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
Trial: NCT05194540
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
Trial: NCT05274659
Drug: KJ103
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Immunoglobulin G Cleaving Enzyme
Trial: NCT05303272
Drug: Abatacept Prefilled Syringe
RxNorm normalized name: abatacept Prefilled Syringe
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
Trial: NCT05019716
Drug: BET Bromodomain Inhibitor ZEN-3694
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05019716
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05019716
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04662931
Drug: crizanlizumab
RxNorm normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
Trial: NCT04804696
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
Trial: NCT04804696
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
Trial: NCT04804696
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
Trial: NCT04499924
Drug: tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg given twice daily orally
Trial: NCT04499924
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
Trial: NCT04499924
Drug: ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle
Trial: NCT04499924
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
Trial: NCT05172700
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.